Victoza® provides significantly greater blood sugar reduction than lixisenatide in new clinical trial
Findings from a head-to-head trial have demonstrated a significantly greater reduction in blood sugar for liraglutide compared to lixisenatide in adults with type 2 diabetes
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Diabetes Patient care Research blood sugar EASD Latest News LIRA-LIXI trial liraglutide lixisenatide type 2 diabetes victoza Source Type: news
More News: Clinical Trials | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Sugar | Victoza